Second-Line Gemcitabine in Refractory Stage IV Non–Small-Cell Lung Cancer: A Phase II Trial
- 1 November 2000
- journal article
- Published by Elsevier in Clinical Lung Cancer
- Vol. 2 (2) , 133-138
- https://doi.org/10.3816/clc.2000.n.026
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy RegimensJournal of Clinical Oncology, 2000
- Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based ChemotherapyJournal of Clinical Oncology, 2000
- Cancer statistics, 2000CA: A Cancer Journal for Clinicians, 2000
- Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of LifeJournal of Clinical Oncology, 1999
- Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapyLung Cancer, 1999
- Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptomsAnti-Cancer Drugs, 1995
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- Chronic oral etoposide in non-small cell lung carcinomaEuropean Journal Of Cancer, 1992